Generic Name: adefovir dipivoxil

Pronunciation: hep-SER-rah

Abbreviation: ADV

Other Market Name: N/A

Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Company: Gilead Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

FDA-approved for the treatment of chronic hepatitis B infection in persons who are 12 years and older.


General Info

  • Hepsera was approved by the U.S. Food and Drug Administration for use by adults with chronic hepatitis B in 2002.
  • In clinical studies, 53 to 64 percent of participants showed improved liver biopsy results after 48 weeks of therapy.


Dosage

Adult Dose: One 10 mg tablet daily, with or without food.

Pediatric Dose: Adolescents age 12 years and older: one 10 mg tablet daily, with or without food.

Dosing Info: Optimal treatment length is unknown. Do not change your dose or stop taking Hepsera without talking to your medical provider.


Side Effects

  • The most common side effects are weakness, headache, stomach pain, nausea, flatulence (intestinal gas), diarrhea and indigestion. Liver transplant patients may experience additional side effects.
  • Hepsera may cause kidney damage, severe liver problems or a serious condition called lactic acidosis (buildup of acid in the blood).
  • Risk of HIV-1 resistance in people with unknown HIV-1 infection or in people with untreated HIV-1 infection.


Drug Interactions

  • Before taking this medication, tell your medical provider and pharmacist about any drugs, supplements and herbs you take, whether prescribed, over-the-counter or illicit.
  • Hepsera should not be used with other medications that contain Viread or other tenofovir-containing products.
  • Additional drug-drug interactions may occur; these are listed in Hepsera’s full prescribing information. Potential interactions are listed at
    hep-druginteractions.org.


Other Info

  • There are no adequate, well-controlled studies in pregnant women who have taken Hepsera. Hepsera should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • The safety of breast feeding while taking Hepsera has not been established, and it is recommended that Hepsera be discontinued if breast-feeding.


For More Info: http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/hepsera/hepsera_pi.pdf

Co-Pay Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment

Patient Assistance Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment

Last Reviewed: March 4, 2019